guanabenz has been researched along with Non-alcoholic Fatty Liver Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Honda, Y; Imajo, K; Iwaki, M; Kasai, Y; Kessoku, T; Kobayashi, N; Kobayashi, T; Nakajima, A; Nogami, A; Ogawa, Y; Ozaki, A; Saito, S; Takahashi, K; Tanaka, K; Yamamoto, A; Yoneda, M | 1 |
| Iwasaki, Y; Kakizaki, S; Matsumoto, S; Mori, M; Ozawa, A; Satoh, T; Trejo, JAO; Uchiyama, Y; Yamada, E; Yamada, M; Yoshino, S | 1 |
1 trial(s) available for guanabenz and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study.
Topics: Clinical Trials, Phase II as Topic; Guanabenz; Humans; Non-alcoholic Fatty Liver Disease; Randomized Controlled Trials as Topic | 2022 |
1 other study(ies) available for guanabenz and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Administration of small-molecule guanabenz acetate attenuates fatty liver and hyperglycemia associated with obesity.
Topics: Administration, Oral; Animals; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Repositioning; Gene Expression Regulation; Guanabenz; Hep G2 Cells; Humans; Lipogenesis; Mice; Non-alcoholic Fatty Liver Disease; Nuclear Proteins; Obesity; Receptors, Leptin | 2020 |